Stock: Banco Santander (SAN)


News: Past 4 years

Announcements


Press Releases

2021

Aug 30, 2021: Banco Santander Dupixent (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
Dupixent (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeksMore than seven times as many patients treated with Dupixent plus topical corticosteroids (TCS) achieved clear or almost clear skin compared to TCS alone at Week 16Dupixent plus TCS reduced overall disease severity by 70% and itch by 49%Results reinforce well-established safety profile of Dupixent - the first ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old PARIS and TARRYTOWN, N.Y. August 30, 2021 - A pivotal Phase 3 trial evaluating Dupixent (dupilumab) for the treatment of children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, a chronic type 2 inflammatory disease, met its primary and all secondary endpoints. The data show adding Dupixent to standard of care topical corticosteroids (TCS) significantly reduced overall disease severity and improved skin clearance, itch, and health-related quality of life measures at 16 weeks compared to TCS alone. Dupixent is the first biologic medicine to show positive results in this young population and remains the only approved biologic medicine in patients 6 years and older with uncontrolled moderate-to-severe atopic dermatitis.

The data reinforce the well-established efficacy and safety profile of Dupixent in other age groups including a lower observed rate of skin infection in the Dupixent group compared with placebo. During the 16-week treatment period Dupixent patients were 50% less likely to experience a skin infection (12% Dupixent, 24% placebo), and the total number of infections was nearly 70% lower (11 Dupixent, 34 placebo). These results add to the extensive LIBERTY AD clinical program the largest Phase 3 clinical trial program in atopic dermatitis involving approximately 3,500 children, adolescents, and adults to date.

Source: West Corporation

Aug 06, 2021: Banco Santander FDA approves Nexviazyme (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
FDA approves Nexviazyme (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells PARIS August 6, 2021 - The U.S. Food and Drug Administration (FDA) has approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilitating muscle disorder that impairs a persons ability to move and breathe. Nexviazyme is an enzyme replacement therapy (ERT) designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of enzyme replacement therapy in Pompe disease. Nexviazyme has been shown in clinical trials to provide patients with improvements in respiratory function and walking distance. Pompe disease is a debilitating and progressive condition that significantly inhibits mobility and breathing, said Bill Sibold, Executive Vice President of Sanofi Genzyme. For decades, weve made it our responsibility to research how to target the M6P receptor, the key pathway for cellular uptake of enzyme replacement therapy. Nexviazyme is a potential new standard of care for people living with late-onset Pompe disease and delivers on our promise to pursue medicines for patients living with rare diseases.Pompe disease affects an estimated 3,500 people in the United States and can present as infantile-onset Pompe disease (IOPD), the most severe form of Pompe disease with rapid onset in infancy, and late-onset Pompe disease (LOPD), which progressively damages muscles over time. LOPD symptoms may present at any age. However, due to the wide spectrum of clinical presentations and progressive nature of the disease, it can take seven to nine years before patients receive an accurate diagnosis. As the disease progresses, people with LOPD may require mechanical ventilation to help with breathing or a wheelchair to assist with mobility.

Targeted delivery to clear glycogen in muscle cells

Source: West Corporation

Aug 05, 2021: Banco Santander Phase 3 trial of Libtayo (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Phase 3 trial of Libtayo (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of deathTrial enrolled patients with locally advanced and metastatic disease with squamous or non-squamous histology, and across all PD-L1 expression levelsLibtayo has now demonstrated improved overall survival as a monotherapy or in combination with chemotherapy in first-line advanced non-small cell lung cancer PARIS and TARRYTOWN, NY August 5, 2021 - The Phase 3 trial of Sanofi and Regenerons PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell lung cancer (NSCLC). Adding Libtayo to chemotherapy significantly improved OS, compared to chemotherapy alone, in the trial that enrolled patients with metastatic or locally advanced disease and tumors with either squamous or non-squamous histology and across all PD-L1 expression levels. These data are planned to form the basis of regulatory submissions in the U.S. and European Union.Libtayo in combination with chemotherapy increased median overall survival to 22 months in patients with advanced non-small cell lung cancer, compared to 13 months with chemotherapy alone, said Miranda Gogishvili, M.D., an oncologist at the High Technology Medical Center, University Clinic, in Tbilisi, Georgia and a trial investigator. Notably, the Phase 3 trial enrolled patients with a variety of challenging-to-treat disease characteristics, as well as those with locally advanced disease. These data add to the growing body of evidence supporting Libtayo in advanced non-small cell lung cancer, which also include the pivotal results for Libtayo monotherapy in cases of high PD-L1 expression.

The decision to stop the trial early was based on a recommendation by the Independent Data Monitoring Committee (IDMC) during a protocol-specified interim analysis. In this top-line initial analysis of 466 patients, combining Libtayo with chemotherapy reduced the risk of death by 29% compared to chemotherapy alone (hazard ratio: 0.71; 95% confidence interval [CI]: 0.53-0.93; p=0.014). Median OS was 22 months (95% CI: 16 months to not evaluable) for Libtayo and chemotherapy, and 13 months (95% CI: 12 to 16 months) for chemotherapy alone. No new Libtayo safety signals were identified in the IDMC analysis, and additional detailed efficacy and safety data will be presented at an upcoming medical meeting.

Source: West Corporation

Jul 29, 2021: Banco Santander Dupixent (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients
Dupixent (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients

Fifth disease that Dupixent has demonstrated positive pivotal resultsPhase 3 trial met its primary endpoints and all key secondary endpoints at 24 weeks, showing Dupixent nearly doubled reduction in itch and urticaria activity scores CSU results further demonstrate the potential of targeting IL-4 and IL-13 via IL-4Ra blockade in improving diseases with components of type 2 inflammationApproximately 300,000 people in the U.S. have moderate to severe CSU that does not respond adequately to antihistamines alone Data continue to support well-established safety profile of Dupixent PARIS and TARRYTOWN, N.Y. July 29, 2021 - A pivotal Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease, met its primary endpoints and all key secondary endpoints at 24 weeks. Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives for biologic-naive patients, compared to those treated with antihistamines alone (placebo) in Study A (the first of two trials) of the LIBERTY CUPID clinical program.

The chronic nature of CSU, coupled with intense itch, causes both a physical and emotional burden on people who have not found an effective treatment, said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. This is the fifth inflammatory disease in which Dupixent has demonstrated a significant improvement in symptoms and disease manifestations in Phase 3 pivotal studies. The success of this trial underscores the agility of our clinical operations team considering the pandemic conditions and underscores our ability to deliver on an aggressive timeline for addressing a significant unmet need for this patient population.

Source: West Corporation

Jul 29, 2021: Banco Santander Online availability of Sanofis half-year financial report for 2021
Online availability of Sanofis half-year financial report for 2021

PARIS July 29, 2021 - Sanofi announces that its half-year financial report for the period ending June 30, 2021 is now available and has been filed with the French market regulator Autorite des marches financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

This document may be found on the companys corporate website: www.sanofi.com and downloaded from the Investors page, under the heading Regulated Information in France.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Media Relations Contacts Ashleigh KossTel: +1 (908) 205-2572Ashleigh.Koss@sanofi.com

Sandrine GuendoulTel.: +33 (0)6 25 09 14 25MR@sanofi.com

Nicolas KressmannTel.: +1 (732) 532-5318Nicolas.Kressmann@sanofi.com

Investor Relations Contacts ParisEva Schaefer-JansenArnaud DelepineNathalie Pham

Investor Relations Contacts North AmericaFelix LauscherFara BerkowitzSuzanne Greco

Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact

Source: West Corporation

Jul 29, 2021: Banco Santander Sales growth accelerated - Full-year guidance raised
Paris, July 29, 2021

Sales growth accelerated - Full-year guidance raised

Q2 2021 sales grew double digit to 8.7 billion (up 12.4% at CER) mainly driven by Dupixent and Vaccines

Q2 2021 business EPS(1) growth of 16.4% at CER driven by sales performance and efficiencies

Progress on implementation of the Corporate Social Responsibility strategy

Key milestone and regulatory achievements on R&D transformation

Full-year 2021 business EPS guidance revised upward

Sanofi Chief Executive Officer, Paul Hudson, commented:

The Sanofi business momentum has accelerated in the second quarter, delivering strong financial results driven by our core growth drivers Dupixent and Vaccines. We continue to deliver on our Play to Win strategy, and our second quarter performance gives us confidence in Sanofis growth trajectory for this year. Consequently, we are raising our full-year EPS guidance to around 12%. Significant progress was made across several clinical and regulatory milestones and in June, we formed the Sanofi mRNA vaccines Center of Excellence with the aim to lead the field in this next chapter of vaccine innovation. We are well on our way making Sanofi more representative of communities we serve, executing on our Diversity and Inclusion strategy and creating a work environment where our people can bring their best selves to transform the practice of medicine.

Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9)(1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q2 2021 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2020 restated business EPS was 5.86; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).

Source: West Corporation

Jul 13, 2021: Banco Santander Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris
Press releaseSource: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)

Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris

PARIS - 07/13/2021 - Tony Estanguet, Chairman of Paris 2024, Paul Hudson, Sanofi Chief Executive Officer, and Serge Weinberg, Chairman of Sanofis Board of Directors, today announced Sanofi will become a Premium Partner of Paris 2024 for the Olympic and Paralympic Games being held in Paris in 2024. Paris will become the second city to host the summer Olympic Games three times with the last Games held in Paris 100 years ago in 1924.

For Sanofi, whose headquarters are based in Paris, this commitment to Paris 2024 is a unique opportunity to engage its 100,000 employees in one of the largest sporting events in the world.

Sanofis commitment to Paris 2024 also highlights the companys societal impact strategy and affirms its commitment to the values of inclusion, diversity and openness to the world, as well as its environmental ambition.

The company welcomes the desire of Paris 2024 foster the values of the Games to make them even more open to the public and more sustainable and intends to contribute by highlighting the benefits of physical activity on health.

Sanofi CEO Paul Hudson added:"Sanofi is proud to contribute to the success of the Olympic and Paralympic Games Paris 2024. It represents a great opportunity to unite our employees around values shared with the Olympics and Paralympics, such as inclusion and diversity, openness to the world, courage, determination and excellence."

Source: West Corporation

Jun 29, 2021: Banco Santander Sanofi launches dedicated vaccines mRNA Center of Excellence
Sanofi launches dedicated vaccines mRNA Center of Excellence

Approximately 400million investment annually to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocationFocus on innovating mRNA vaccines beyond pandemic to routine use in diseases with high unmet needExpected minimum of six clinical candidates by 2025 PARIS June 29, 2021 - Sanofi will invest approximately 400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy lEtoile, Lyon (France).During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. However, key areas of innovation such as thermostability and tolerability improvements will be critical to unlock the applications of mRNA in routine vaccination against a broader set of infectious diseases and across all ages. The Sanofi mRNA vaccines Center of Excellence aims to lead the field in this next chapter of vaccine innovation, said Jean-Francois Toussaint, Global Head of Research and Development, Sanofi Pasteur.

The Center of Excellence will enable acceleration of the vaccines mRNA portfolio developed through the Translate Bio collaboration established in 2018 and expanded in 2020.

Source: West Corporation

Jun 28, 2021: Banco Santander Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season MEDLEY is the third pivotal trial to report positive data for nirsevimab; regulatory submissions planned for the first half of 2022 PARIS June 28, 2021 - In positive topline results from the Phase 2/3 MEDLEY trial, nirsevimab showed a similar safety and tolerability profile compared to palivizumab when administered to preterm infants or those with chronic lung disease (CLD) or congenital heart disease (CHD) entering their first respiratory syncytial virus (RSV) season.3 Safety and tolerability were assessed by the occurrence of all treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs).

RSV, a seasonal virus that typically circulates in autumn through spring in temperate regions, is the most common cause of lower respiratory tract infections (LRTI) and the leading cause of hospitalizations in all infants.1,2,4These data for nirsevimab are important as they show a safety and tolerability profile comparable to the only available preventative option against lower respiratory tract infections caused by RSV for preterm infants and those with health conditions, said Dr. Joseph Domachowske, Professor of Pediatrics and Professor of Microbiology and Immunology at the State University of New York, Upstate Medical Center and MEDLEY trial primary investigator. Given the typical RSV season lasts nearly five months, there is a potential advantage to providing a preventative option that could help protect all infants with one dose for the entire season.MEDLEY is the third pivotal trial to report positive data for nirsevimab. In April, Sanofi reported that nirsevimab met its primary endpoint of achieving a statistically significant reduction of LRTI caused by RSV in healthy preterm and term infants in the Phase 3 MELODY trial. Coupled with recently published Phase 2b trial results, MELODY and MEDLEY results are part of a robust body of evidence demonstrating the potential of nirsevimab to provide RSV protection to all infants. Results from the MELODY and MEDLEY trials will be presented at forthcoming scientific congresses and, along with the Phase 2b results, will form the basis of global regulatory submissions planned for 2022.

Source: West Corporation

Jun 28, 2021: Banco Santander Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

PARIS and TARRYTOWN, N.Y. June 28, 2021- Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agencys Committee for Medicinal Products for Human Use.

Data from a single-arm Phase 3 open label extension (OLE) trial showed the long-term safety profile in adults with moderate-to-severe atopic dermatitis treated with Dupixent and observed up to three years was generally consistent with what was observed in the controlled pivotal Phase 3 trials. The OLE trial assessed the long-term safety of Dupixent 300 mg weekly in adults who had previously participated in Dupixent trials or had been screened for a Phase 3 trial. The approved Dupixent dose in adults is 300 mg every other week.

Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating. Moderate-to-severe atopic dermatitis is characterized by intense persistent itch and skin lesions that can cover much of the body, resulting in skin dryness, cracking, redness or darkening, crusting and oozing. Itch is one of the most burdensome symptoms for patients. Moderate-to-severe atopic dermatitis can also have a substantial emotional and psychosocial impact on patients and their families, causing sleep disturbance, anxiety, depression and feelings of isolation.

Source: West Corporation

Jun 26, 2021: Banco Santander Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
Sanofi announced today that its Q2 2021 Memorandum for modelling purposes is available on the "Investors" page of the company's website:

Source: West Corporation

Jun 25, 2021: Banco Santander Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitorLibtayo now approved by the European Commission for three advanced cancers PARIS and TARRYTOWN, NY June 25, 2021 The European Commission (EC) has approved Sanofi and Regenerons PD-1 inhibitor Libtayo (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).

BCC is the most common type of skin cancer worldwide, representing up to 80% of non-melanoma skin cancers, and incidence is increasing across many European countries. While the large majority of BCCs are caught early and easily cured with surgery and/or radiation, a small proportion of cases can develop into advanced BCC and penetrate deeper into surrounding tissues (locally advanced) or spread to other parts of the body (metastatic), becoming more difficult to treat.

Since its launch in Europe just two years ago, Libtayo has redefined the standard of care for advanced CSCC and has the potential to do the same in advanced BCC, said Peter C. Adamson, M.D., Global Development Head, Oncology at Sanofi. Together with Regeneron, were committed to addressing gaps in the treatment of advanced forms of non-melanoma skin cancer.

Source: West Corporation

Jun 25, 2021: Banco Santander Sanofi: Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with 50% PD-L1 expression
Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with 50% PD-L1 expression

Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that included challenging-to-treat patient populationsLibtayo now approved by the European Commission for three advanced cancers PARIS and TARRYTOWN, NY June 25, 2021 - The European Commission (EC) has approved Sanofi and Regenerons PD-1 inhibitor Libtayo (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (NSCLC) whose tumor cells have 50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. Patients must have metastatic NSCLC or locally advanced NSCLC and not be a candidate for definitive chemoradiation.

Libtayo is now approved for three advanced cancers in the European Union. The EC also approved Libtayo in advanced basal cell carcinoma, the first treatment to be indicated for those patients who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). In 2019, Libtayo was approved by the EC as the first treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. Across all of its approved indications, Libtayo had a generally consistent safety profile. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue during or after treatment with Libtayo.We are confident that Libtayo has the potential to become an important treatment option for patients in the European Union and thank all the investigators, patients and their families who helped us reach this milestone, said Peter C. Adamson, M.D., Global Development Head, Oncology at Sanofi. We are anticipating results from our ongoing Phase 3 trial of Libtayo plus chemotherapy in patients with advanced non-small cell lung cancer and remain committed to studying Libtayo in additional cancer settings where there is the potential to improve the outcome for patients.

Source: West Corporation

Jun 18, 2021: Banco Santander European Commission approves Aubagio (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
European Commission approves Aubagio (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

PARIS June 18, 2021 - The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study. The approval confirms Aubagio as the first oral multiple sclerosis (MS) therapy for first-line treatment of children and adolescents with MS in the European Union.

MS affects an estimated 2.8 million people around the world, with children and adolescents representing at least 30,000 of those impacted.1,2 Pediatric MS is a rare condition and onset follows a relapsing-remitting disease course in 98 percent of pediatric patients.3,4 Compared with adult-onset MS, pediatric patients often present with higher relapse rates and a greater lesion burden.5 Due to the earlier onset of disease, irreversible disability and secondary progression often occur at an earlier age than with adult counterparts.3 The symptoms of MS can impact all aspects of a young persons life from physical health to social development and self-esteem.6Pediatric multiple sclerosis remains an area of significant unmet medical need, said Erik Wallstrom, MD, PhD, Therapeutic Area Head, Neurology Development at Sanofi Genzyme. The European approval of Aubagio in pediatrics means young people with MS have a new treatment option, and importantly - one that can offer meaningful improvement in managing this serious disease. Aubagio was initially approved in the EU in 2013 for the treatment of adult patients with RRMS and the EC approval for the pediatric indication provides an additional year of marketing protection in the European Union.

Source: West Corporation

Jun 08, 2021: Banco Santander Sanofi launches its new global employee share ownership plan
PARIS - June 7, 2021 - Sanofi today launches Action 2021, its global employee share ownership plan, open to 92,000 employees in 73 countries. The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company.

Source: West Corporation

Jun 07, 2021: Banco Santander Sanofi launches its new global employee share ownership plan
PARIS - June 7, 2021 - Sanofi today launches Action 2021, its global employee share ownership plan, open to 92,000 employees in 73 countries. The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company.

Source: West Corporation

Jun 04, 2021: Banco Santander Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical researchCollaborating on the Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofis investigational amcenestrant in estrogen receptor-positive (ER+) patients who prematurely discontinue standard therapy and have high risk of disease recurrenceParties to finalize full terms of this cooperative effortAdditional treatment options in early breast cancer are needed to help prevent patients from developing advanced, incurable disease and would represent a significant treatment advance PARIS June 4, 2021 Sanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and the Alliance Foundation Trials (AFT), to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting. The Phase 3 AMEERA-6 study will evaluate the efficacy and safety of Sanofis amcenestrant vs tamoxifen for women with estrogen receptor-positive (ER+) breast cancer who were unable to continue their adjuvant aromatase inhibitor (AI) therapy.

Together with our research partners, BIG conducts landmark, practice-changing trials that can have a significant impact on the lives of women with breast cancer, said David Cameron, Chair of the BIG Executive Board.Adjuvant therapy helps prevent and delay the progression of disease into the later setting. However, current adjuvant therapies, like AIs, can have side effects for some women, which may cause them to discontinue the medication prematurely. Amcenestrant may be a potential option for women in this setting and we look forward to working with Sanofi, EORTC and AFT to investigate this further.

Source: West Corporation

Jun 03, 2021: Banco Santander Sanofi launches 3 million Planet Mobilization fund to support employees environmental projects
Sanofi launches 3 million Planet Mobilization fund to support employees environmental projects

This year, Sanofi will fund three employee teams for their environmental programs in Vietnam, Ireland, France, Belgium and ItalyIn April 2021, Sanofi expanded its social commitments, including its global environmental sustainability program, Planet Mobilization PARIS June 3, 2021 As part of a long-standing commitment to reduce the environmental footprint of the companys products and activities, Sanofi launched a 3 million Planet Mobilization fund to support employee ideas and projects that will further contribute to a healthier environment. This year, three Sanofi teams will have their projects funded.

For several years, Sanofi has been implementing a global environmental roadmap, Planet Mobilization, which is embedded in Sanofis long-term strategy. The program covers all Sanofi activities and sites and the entire lifecycle of products, from raw materials used in production all the way to their disposal.

Because the fight against climate change is also a fight for the health and well-being, Sanofi commits to Planet Mobilization says Philippe Luscan, Executive Vice President, Global Industrial Affairs. We strongly believe our employees are the most powerful agents of positive change for people, and for the planet. Its with this ambition and objectives in mind that we decided to create a fund of 3 million to finance ideas and projects coming from our employees in support of our environmental ambition. Today, it is fair to say that teams all over the world took up the challenge, even beyond our expectations. Thats collective intelligence in motion.

Source: West Corporation

Jun 01, 2021: Banco Santander Sanofi provides update on venglustat clinical program
Sanofi provides update on venglustat clinical program

PARIS JUNE 1, 2021 A pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease (ADPKD) did not meet futility criteria, and the company has halted the clinical program in ADPKD. The safety profile of venglustat remains consistent with previously reported results with more than 500 patients treated to date over a period of up to four years across all clinical programs. Biomarker data from the study confirmed venglustat effectively inhibits the glycosphingolipid (GSL) pathway by demonstrating a reduction in GL-1, a lipid that accumulates in certain cells.

The STAGED-PKD study was stopped for futility following an independent analysis of the annualized rate of change in total kidney volume (TKV) in patients receiving venglustat compared to placebo. Trends from the analysis showed venglustat did not provide a meaningful reduction in TKV growth rate, the primary endpoint of stage 1 of the Phase 2/3 study. This interim analysis suggests the reduction of GSLs may not play a significant role in the prevention of kidney cyst growth, and as such, may not be a primary pathway associated with the progression of ADPKD. The investigational research of venglustat in ADPKD was an attempt to explore a novel biological role for GSLs beyond the established role of these lipids in lysosomal storage diseases (LSDs). The venglustat development program started with our confidence in the promise of a potential breakthrough treatment to address the unmet needs of people living with lysosomal storage disorders, said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. In parallel, we set out to evaluate venglustat in autosomal dominant polycystic kidney disease, a leading cause of kidney transplant. This outcome is not what we hoped for, especially for these patients. However, our research has furthered the scientific understanding of ADPKD by demonstrating that modulating the GSL pathway is insufficient to restore kidney function in adults affected by this disease.

Source: West Corporation

May 27, 2021: Banco Santander Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants A booster study program will begin in the coming weeks to complement Phase 3 trialPending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021 PARIS and LONDON May 27, 2021 Today, Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity oftheir adjuvanted recombinant-protein COVID-19 vaccine candidate. The global, randomized, double-blind placebo-controlled Phase 3 study will include more than 35,000 volunteersaged 18 and olderfrom several countries, including sites in the US, Asia, Africa, and Latin America.

The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naive adults, with secondary endpoints being the prevention of severe COVID-19 disease and prevention of asymptomatic infection. In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original D.614 virus (Wuhan), while a second stage will evaluate a second formulation targeting the B.1.351 (South African) variant. Recent scientific evidence1 shows that antibodies created against the B.1.351 variant may provide broad cross-protection against other more transmissible variants. The design of the Phase 3, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants.

Source: West Corporation

May 19, 2021: Banco Santander Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclibOverall safety profile of amcenestrant with palbociclib is consistent with what was observed in monotherapy, without signs of significant cardiac or ocular side effects The Phase 3 combination study (AMEERA-5) of amcenestrant with palbociclib in the first-line setting was initiated in October 2020 and is successfully recruiting patients The pivotal study (AMEERA-3) of amcenestrant versus physicians choice in locally advanced or metastatic estrogen receptor-positive (ER+) breast cancer is fully recruited; readout expected in H2 2021 PARIS May 19, 2021 Phase 1 data from the AMEERA-1 study evaluating amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. In a pooled analysis, amcenestrant in combination with palbociclib showed encouraging antitumor activity in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC).

These early clinical data show that the combination of amcenestrant with palbociclib achieved encouraging antitumor activity, said Sarat Chandarlapaty, M.D., Ph.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center. The analysis also demonstrated no clinically significant cardiac or ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. Its notable to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.

Source: West Corporation

May 17, 2021: Banco Santander Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groupsHigh immune response after a single dose in patients with prior infection shows strong booster potentialGlobal Phase 3 study expected to start in the coming weeks PARIS and LONDON May 17, 2021 The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.

The Phase 2 interim results showed 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old) and across all doses, with acceptable tolerability and with no safety concerns. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old). After a single injection, high neutralizing antibody levels were generated in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine.

Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases, said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. With these favorable results, we are set to progress to a global Phase 3 efficacy study. We look forward to generating additional data and working with our partners around the world to make our vaccine available as quickly as possible.

Source: West Corporation

May 17, 2021: Banco Santander Pivotal data at ATS 2021 show Dupixent (dupilumab) significantly reduced asthma attacks and improved lung function in children
Pivotal data at ATS 2021 show Dupixent (dupilumab) significantly reduced asthma attacks and improved lung function in children

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patientsResults further support well-established safety profile of DupixentFDA decision for children with moderate-to-severe asthma expected by October 21, 2021 PARIS and TARRYTOWN, N.Y. May 17, 2021 Detailed results from a Phase 3 trial showed Dupixent (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation. Dupixent also significantly improved overall asthma symptom control and reduced an airway biomarker of type 2 inflammation that plays a major role in asthma, called fractional exhaled nitric oxide (FeNO). These data are being presented at the 2021 American Thoracic Society International Conference (ATS 2021) and featured in the Breaking News: Clinical Trial Results in Pulmonary Medicine Scientific Symposium.Children living with uncontrolled moderate-to-severe asthma experience serious and persistent symptoms that can impact many crucial aspects of their lives including school, sleep and exercise, says Leonard B. Bacharier, M.D., Professor of Pediatrics and Director of the Center for Pediatric Asthma Research, Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center in Nashville, Tennessee and principal investigator of the trial. The trial results show that dupilumab, when added to standard of care therapy, significantly reduced asthma attacks, rapidly improved lung function and improved asthma control, which is especially important to these children during a particularly formative time in their lives.Asthma is the most common chronic disease in children, with approximately 75,000 children aged 6 to 11 years living with the uncontrolled moderate-to-severe form of the disease in the U.S., and many more worldwide. Despite treatment with current standard-of-care inhaled corticosteroids and bronchodilators, these children may continue to experience serious symptoms such as coughing, wheezing and difficulty breathing. They also may require the use of multiple courses of systemic corticosteroids that carry significant risks. Children who have asthma with underlying type 2 inflammation, which is the most common cause of asthma in children, are more likely to have poor asthma control, more frequent asthma attacks and symptoms that interfere with day-to-day activities.

The Phase 3, randomized, double-blind, placebo-controlled VOYAGE trial evaluated the efficacy and safety of Dupixent (100 mg or 200 mg every two weeks, based on weight) combined with standard-of-care asthma therapy in 408 children with uncontrolled moderate-to-severe asthma. Two pre-specified populations with evidence of type 2 inflammation were evaluated for the primary analysis: 1) patients with baseline blood eosinophils (EOS) 300 cells/l (n=259) and 2) patients with FeNO 20 parts per billion (ppb) or EOS 150 cells/l; n=350.

Source: West Corporation

May 06, 2021: Banco Santander Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions

Source: West Corporation

Apr 28, 2021: Banco Santander Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
General Medicines core assets grew 4.4%, while GBU sales were down 3.8%

Source: West Corporation

Apr 26, 2021: Banco Santander Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
Nirsevimab met its Phase 3 primary endpoint earlier than anticipated; regulatory submissions for all-infant indication to begin in 2022.

Source: West Corporation

Apr 24, 2021: Banco Santander New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated response rates across a broad population, and the impact of Dupixent on disease extent and severity, quality of life (QoL), and itch. These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Source: West Corporation

Apr 07, 2021: Banco Santander Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi's long-term strategy, the companyaEUR(TradeMark)s commitment is based on four essential pillars in which Sanofi is uniquely positioned to make a difference: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees.

Source: West Corporation

Mar 12, 2021: Banco Santander Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID19 vaccine candidate
Expected to enroll 415 participants; interim results expected in Q3 2021

Source: West Corporation

Feb 12, 2021: Banco Santander The Lancet publishes Libtayo(Registered) (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50%
PARIS and TARRYTOWN, N.Y. aEUR February 12, 2021 aEUR The Lancet today published results from a pivotal trial designed to evaluate the investigational use of the PD-1 inhibitor LibtayoA(Registered) (cemiplimab) compared to platinum-doublet chemotherapy in patients with locally advanced or

Source: West Corporation

Feb 10, 2021: Banco Santander FDA approves Libtayo (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor LibtayoA(Registered) (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.

Source: West Corporation

Feb 05, 2021: Banco Santander Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
Execution of strategic plan announced in December 2019 is well underway with key growth drivers delivering New business focus in General Medicines and Consumer Healthcare designed to accelerate SanofiaEUR(TradeMark)s growth, cash flow generation, and improve profitability

Source: West Corporation

2020

Dec 18, 2020: Banco Santander Availability of the Q4 2020 Memorandum for modelling purposes
Paris, France - December 17, 2020 - Sanofi announced today that its Q4 2020 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2020

Source: West Corporation

Dec 15, 2020: Banco Santander Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
Sanofi has signed on December 10th a renewed partnership agreement with the World Health Organization (WHO), consolidating a 20-year collaboration to fight some of the most Neglected Tropical Diseases (NTDs) and supporting the WHO in its commitment to sustainably eliminate sleeping sickness before 2030.

Source: West Corporation

Dec 11, 2020: Banco Santander CHMP recommends approval of Plavix (clopidogrel) with aspirin in adults for certain types of strokes
The European Medicines AgencyaEUR(TradeMark)s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an additional indication for PlavixA(Registered) (clopidogrel) in adult patients with high-risk transient ischemic attack (TIA) or minor ischemic stroke (IS). This new indication includes Plavix used alongside aspirin within 24 hours of an event and continued for 21 days, followed by long-term single anti-platelet therapy.

Source: West Corporation

Dec 10, 2020: Banco Santander Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years Insufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groups Companies plan a Phase 2b study with an improved antigen formulation With support from BARDA as part of Operation Warp Speed, study to start in February 2021, including a proposed comparison with an authorized COVID-19 vaccine Product availability now expected in Q4 2021 pending successful completion of the development plan

Source: West Corporation

Nov 30, 2020: Banco Santander Dupixent(Registered) (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
Pivotal trial showed more than four times as many children achieved itch reduction and more than three times as many children achieved clear or almost clear skin with Dupixent plus topical corticosteroids (TCS) compared to TCS alone

Source: West Corporation

Nov 19, 2020: Banco Santander European Commission approves Supemtek(Registered) (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
The European Commission has granted a marketing authorization for SupemtekA(Registered), a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older. Supemtek is the first and only recombinant influenza vaccine now approved in the European Union.

Source: West Corporation

Nov 19, 2020: Banco Santander FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
PARIS - November 18, 2020 - The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for avalglucosidase alfa for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid I-glucosidase deficiency). The target action date for the FDA decision is May 18, 2021.

Source: West Corporation

Nov 19, 2020: Banco Santander Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
PARIS - November 18, 2020 aEUR" The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton's tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia (ITP). In addition, following positive Phase 1/2 study results, a Phase 3 study evaluating rilzabrutinib for ITP has been initiated. Rilzabrutinib received orphan drug designation from the FDA for the treatment of ITP in October 2018.

Source: West Corporation

Oct 28, 2020: Banco Santander Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
Sanofi and GSK have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.

Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility. Both Companies intend to contribute to COVAX's ambition to ensure successful COVID-19 vaccines reach those in need, whoever they are and wherever they live, once they obtain appropriate approvals.

Source: West Corporation

Oct 26, 2020: Banco Santander Dupixent(Registered) (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
Additional positive results were announced from Part A of a pivotal Phase 3 trial evaluating the investigational use of DupixentA(Registered) (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). As previously reported, the trial met both of its co-primary and all key secondary endpoints. New late-breaking data showing additional improvements in disease severity and extent at the microscopic level, as well as normalization of gene expression pattern associated with type 2 inflammation, were presented at the virtual American College of Gastroenterology (ACG) Annual Scientific Meeting and the United European Gastroenterology (UEG) Week Virtual 2020.

Source: West Corporation

Oct 16, 2020: Banco Santander CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for DupixentA(Registered) (dupilumab), recommending to extend the approval in the European Union (EU) to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for systemic therapy.

Source: West Corporation

Oct 15, 2020: Banco Santander Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.

Source: West Corporation

Oct 02, 2020: Banco Santander EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for avalglucosidase alfa, for long-term enzyme replacement therapy for the treatment of patients with Pompe disease. Avalglucosidase alfa is an investigational enzyme replacement therapy, which, if approved, would offer a potential new standard of care for patients with Pompe disease.

Source: West Corporation

Sep 23, 2020: Banco Santander Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
PARIS and LONDON aEUR" September 22, 2020 aEUR" Sanofi and GSK have today signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021.

aEURoeTodayaEUR(TradeMark)s announcement showcases our unwavering commitment to develop a COVID-19 vaccine that is available to everyone when it comes to market,aEUR said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. aEURoeTo address a global health crisis of this magnitude, it takes partnerships and we are grateful to Canada for its collaboration, and to GSK for partnering with us to develop a safe and effective vaccine.aEUR

Source: West Corporation

Sep 18, 2020: Banco Santander Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation

PARIS - September 18, 2020 - Sanofi today announced the appointment of Dr. Jean-Christophe Rufin as President of the Sanofi Espoir Corporate Foundation. Jean-Christophe Rufin succeeds Xavier Darcos, who presided over the Foundation since 2015.

"We are delighted that Dr. Jean-Christophe Rufin has accepted to serve as President of the Sanofi Espoir Foundation", said Serge Weinberg, President of Sanofi. "His experience as both a physician and diplomat gives him a broad expertise in humanitarian and public health issues around the world. He will enable us to step up our response to health distress among vulnerable populations. Through his literary work, he has amply demonstrated his humanist commitments and his capacity to understand international realities."

The Sanofi Espoir Foundation's mission is to help reduce health inequalities among the world's most vulnerable populations. At the end of 2019, the Foundation was coordinating 77 projects in 50 countries in four main areas of focus:

The fight against pediatric cancers in countries with limited resourcesCombating maternal and neonatal mortality in low- and middle-income countriesAccess to healthcare for people in vulnerable situations in FranceSupport for families in the event of health crises "It is a great honor for me to preside over the Sanofi Espoir Foundation," said Dr. Jean-Christophe Rufin. "I salute the work accomplished over the past 10 years to reduce health inequalities, and I am committed to taking this even further, by broadening the Sanofi Espoir Foundation's areas of involvement and methods for action."

Source: West Corporation

Sep 18, 2020: Banco Santander Positive pivotal data for Libtayo (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
Positive pivotal data for Libtayo (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial31% objective response rate seen in trial patients, and an estimated 85% of responses were ongoing at one year PARIS and TARRYTOWN, N.Y. - September 18, 2020 - Positive results from the pivotal Phase 2 trial for the PD-1 inhibitor Libtayo (cemiplimab) in patients with locally advanced basal cell carcinoma (BCC) who had progressed on or were intolerant to hedgehog inhibitor (HHI) therapy were shared in a late-breaking presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

The data will form the basis of regulatory submissions, including in the U.S. and European Union.

"Advanced basal cell carcinoma can be an unrelenting, highly disfiguring disease, and there are no approved treatment options once a patient progresses on or becomes intolerant to hedgehog inhibitors," said Alexander Stratigos, M.D., Professor of Dermatology at the University of Athens Medical School at Andreas Sygros Hospital and a trial investigator. "This is the first time a prospective trial of an investigational medicine has shown a clinical benefit in this patient population, and the Libtayo data provide hope for this difficult-to-treat cancer."

Per independent central review, the objective response rate (ORR) was 31% among Libtayo-treated patients (n=84; 95% confidence interval [CI]: 21-42%), with a median follow-up of 15 months (range: 1-25 months). This included a 6% (n=5) complete and 25% (n=21) partial response rate. This is an increase from the ORR shared in May and includes two responses that were confirmed after the initial data analysis. Responses were seen regardless of baseline PD-L1 expression in tumor cells.

Source: West Corporation

Sep 14, 2020: Banco Santander FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis
FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

Designation based on positive results from Part A of pivotal Phase 3 trial Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE)There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients' ability to swallow and eatDesignation supports Dupixent's potential in another disease driven by type 2 inflammation PARIS and TARRYTOWN, N.Y., September 14, 2020 - The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent (dupilumab) for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE). The designation for this investigational use is based on positive results from Part A of a Phase 3 trial in patients with EoE.

There are currently no FDA-approved medicines for EoE, a chronic and progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly. Over time, excessive type 2 inflammation causes scarring and narrowing of the esophagus, making it difficult to swallow. If left untreated, EoE can affect a patient's ability to eat and cause food to become stuck after being swallowed (food impaction), which can lead to a medical emergency.

Source: West Corporation

Sep 10, 2020: Banco Santander New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A
The New England Journal of Medicine today published positive final results from the Phase 1/2a trial evaluating the safety, tolerability and pharmacokinetics of BIVV001 (rFVIIIFc-VWF-XTEN) in adult patients with severe hemophilia A. BIVV001 is an investigational factor VIII therapy designed to provide higher bleed protection in a once-weekly prophylactic treatment regimen. Sanofi and Sobia"cents (STO:SOBI) collaborate on the development and commercialization of BIVV001.

Source: West Corporation

Sep 08, 2020: Banco Santander Dupixent (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma
With more than 2,200 patients enrolled, Phase 3 open-label extension trial is the largest of a biologic medicine ever conducted in asthmaData up to three years show a safety profile consistent with pivotal asthma trialsDupixent is the only biologic to demonstrate sustained improvements in lung function and asthma exacerbations across a broad patient population with type 2 inflammationData to be presented at the 2020 ERS International Congress PARIS and TARRYTOWN, NY - September 8, 2020 - New results from a Dupixent (dupilumab) Phase 3 open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma. Data from the trial will be presented during a live session at the virtual 2020 European Respiratory Society (ERS) International Congress.

"These data suggest Dupixent may slow the progressive decline in lung function that many patients with moderate-to-severe asthma experience, as shown by the sustained improvement in lung function for up to three years. Further, patients on Dupixent maintained asthma control and reduced rates of severe asthma attacks that may result in hospitalizations," said Michael Wechsler, M.D., M.M.Sc., Director of the National Jewish Cohen Family Asthma Institute in Denver, Colorado, and principal investigator of the trial. "This reinforces the importance of Dupixent as a continuous, long-term treatment option to improve patients' ability to breathe and maintain control of their asthma, particularly in those with higher markers of underlying type 2 inflammation."

The analyses to be presented at ERS include more than 2,200 patients who previously participated in Dupixent asthma trials, including three pivotal trials that lasted between 24 and 52 weeks. Patients entered the extension trial after finishing active treatment or placebo in the initial trials and were treated for up to an additional two years, providing up to three years of treatment data in total. The safety analyses included patients from all three pivotal asthma trials and the efficacy and biomarker analyses included patients who are not dependent on oral corticosteroids (OCS) from the pivotal Phase 2b and Phase 3 QUEST trials. Additional long-term efficacy data in OCS-dependent patients will be presented at a later congress. Results showed:

Source: West Corporation

Sep 03, 2020: Banco Santander Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Pre-clinical studies show promising safety and immunogenicity.Over 400 participants being enrolled in Phase 1/2 study Pending positive Phase 1/2 data, companies aim to move into Phase 3 by end of 2020Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021 PARIS and LONDON - Sept. 3, 2020 - Sanofi and GSK today started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.

The Phase 1/2 clinical trial is a randomized, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the COVID-19 vaccine candidate. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States.

The companies anticipate first results early December 2020 which will support the initiation of a Phase 3 trial in December 2020. If data are sufficient for licensure application, the plan is to request regulatory approval in the first half of 2021.

Sanofi is leading the clinical development and registration of the COVID-19 vaccine. Preclinical data showed an acceptable reactogenicity profile and data based on two injections of the adjuvanted recombinant vaccine showed high levels of neutralizing antibodies that are comparable to levels in humans who recovered from the COVID-19 infection. Pre-clinical results will be published later this year. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021.

Source: West Corporation

Jul 31, 2020: Banco Santander Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine

Promising vaccine candidate selected by U.S. government's Operation Warp SpeedU.S. government to provide funding up to $2.1 billion for development, including clinical trials and manufacturing scale-up, and delivery of an initial 100 million dosesOngoing discussions with the European Commission, with France and Italy on the negotiation team, and other governments to ensure global access to a novel coronavirus vaccine PARIS and LONDON - July 31, 2020 - Sanofi and GSK today announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology.

Collaborating with the U.S. Department of Health and Human Services (HHS) and Department of Defense will help fund the development activities and secure scale-up of Sanofi's and GSK's manufacturing capabilities in the United States for the recombinant protein-based, adjuvanted vaccine, resulting in a significant increase in capacity.

The U.S. government will provide up to $2.1 billion, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses of the vaccine. Sanofi will receive the majority of the U.S. government funding. The U.S. government has a further option for the supply of an additional 500 million doses longer term. This helps the U.S. government's Operation Warp Speed goals of providing millions of doses of a safe and effective COVID-19 vaccine.

Source: West Corporation

Jul 31, 2020: Banco Santander Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

Discussions relate to vaccine candidate using Sanofi's recombinant protein-based technology combined with GSK's pandemic adjuvant systemBoth companies are committed to making their COVID-19 vaccine affordable and available globally PARIS and LONDON - July 31, 2020 - Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established adjuvant technology. The doses would be manufactured in European countries including France, Belgium, Germany and Italy. This marks a key milestone in protecting and serving the European population against COVID-19.

"Today's announcement helps to ensure that millions of Europeans will have access to a potential vaccine protecting against COVID-19, once proven safe and effective. It has been our steadfast commitment to provide a vaccine that is affordable and accessible to everyone, and we are grateful to the European Commission for their ongoing engagement and shared support of this effort," said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. "Together with GSK, we are working relentlessly to develop and produce a vaccine to address this global health crisis."

Source: West Corporation

Jul 30, 2020: Banco Santander Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial
Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1 Results published in New England Journal of MedicineThe investigative immunization demonstrated sustained protection across a typical five-month RSV season with a single dose1Sanofi will host a nirsevimab R&D investor event today at 5 p.m. CET/11 a.m. ET PARIS - July 30, 2020 - Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI), mainly bronchiolitis and pneumonia, and hospitalizations caused by respiratory syncytial virus (RSV) in healthy preterm infants.

Published in the New England Journal of Medicine, results from this trial demonstrate for the first time that a single dose monoclonal antibody can significantly reduce medically attended RSV LRTI in infants through the full RSV season.1

"The data for nirsevimab are exciting, as they highlight the potential for this innovative approach to protect infants from RSV with just one injection for the entire season," said Dr. Joseph Domachowske, study author, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University. "Nirsevimab offers the important potential to reduce hospitalizations and emergency department and in-office visits, which are a significant burden for healthcare systems."

Source: West Corporation

Jul 30, 2020: Banco Santander Online availability of Sanofi's half-year financial report for 2020
PARIS - July 29, 2020 - Sanofi announces that its half-year financial report for the period ending June 30, 2020 is now available and has been filed with the French market regulator Autorite des marches financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

Source: West Corporation

Jul 29, 2020: Banco Santander Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Q2 2020 sales results reflect the strong performance of Dupixent more than offset by COVID-19 related negative effects on Vaccines, General Medicines and CHC

Source: West Corporation

Jul 29, 2020: Banco Santander Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Agreement relates to vaccine candidate using Sanofi's recombinant protein-based technology combined with GSK's pandemic adjuvant systemBoth companies are committed to making their COVID-19 vaccine candidate affordable and available globallyOngoing discussions with the European Commission, with France and Italy on the negotiation team, and other governments to ensure global access to a novel coronavirus vaccine PARIS and LONDON - July 29, 2020 - Sanofi and GSK have reached an agreement, subject to final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology.

"With our partner GSK, we are pleased to cooperate with the UK government as well as several other countries and global organizations as part of our ongoing efforts to develop a safe and effective vaccine and make it available as quickly as possible. We greatly appreciate the UK government's support of this shared vision," said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur.

Roger Connor, President of GSK Vaccines added, "We believe that this adjuvanted vaccine candidate has the potential to play a significant role in overcoming the COVID-19 pandemic, both in the UK and around the world. We thank the UK Government for confirmation of purchasing intent, which supports the significant investment we are already making as a company to scale up development and production of this vaccine."

Source: West Corporation

Jul 06, 2020: Banco Santander Availability of the Pre-quarterly Results Communication
Availability of the Pre-quarterly Results Communication

Paris, France - July 6, 2020 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q2-results-2020

Source: West Corporation

Jul 02, 2020: Banco Santander Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients

PARIS and TARRYTOWN, N.Y. - July 2, 2020 - Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).

Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400 mg who were mechanically ventilated at baseline) that did not reach statistical significance and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline1. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara, 3% placebo).

Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara (800 mg). Detailed results will be submitted to a peer-reviewed publication later this year.

The primary analysis group included 194 patients who were critically ill with COVID-19 and receiving mechanical ventilation at the time of enrolment. The primary endpoint assessed the percentage of patients who achieved at least a 1-point change from baseline on a 7-point scale, which consisted of 1) death; 2) hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) discharged from hospital. A second cohort, which was partially recruited (n=27), compared Kevzara 800 mg versus placebo.

Source: West Corporation

Jun 23, 2020: Banco Santander Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseasesTranslate Bio to receive $425 million in upfront payment and common stock equity investment and overall is eligible to receive up to $1.9 billion of potential milestones/payments as well as tiered royalties on worldwide sales of developed vaccinesSanofi to receive exclusive worldwide rights to develop, manufacture and commercialize infectious disease vaccines using Translate Bio technologyThe expanded collaboration brings together Translate Bio's leading mRNA technology and manufacturing with Sanofi's world class vaccine development and distribution PARIS and LEXINGTON, MASS. - June 23, 2020 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases.

The expansion of this agreement will further unite Translate Bio's expertise and knowledge from more than 10 years of mRNA research and development with Sanofi's leadership in vaccine research and development. Under the expansion agreement, Translate Bio will receive a total upfront payment of $425 million, consisting of a $300 million cash payment and a private placement common stock investment of $125 million at $25.59 per share representing a 50 percent premium to the 20-day moving average share price prior to signing. Translate Bio will also be eligible for potential future milestones and other payments up to $1.9 billion, including $450 million of milestones under the 2018 agreement. Of these potential milestones and other payments, approximately $360 million are anticipated over the next several years, inclusive of COVID-19 vaccine development milestones. In addition, Translate Bio is also eligible to receive tiered royalty payments based upon worldwide sales of the developed vaccines. Sanofi Pasteur will pay for all costs during the collaboration term. Under this agreement Sanofi Pasteur will receive exclusive worldwide rights for infectious disease vaccines.

Source: West Corporation

Jun 23, 2020: Banco Santander Sanofi's virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
Sanofi's virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients

R&D strategy driving pipeline momentum, productivity and innovationSignificant progress made since December 2019 on priority pipeline programs that have the potential to transform patient careFirst multiple sclerosis patient has been enrolled in the Phase 3 program for brain penetrant BTK inhibitor '168Positive THOR-707 "not-alpha" IL-2 first-in-human biomarker data Accelerated development timeline for COVID-19 recombinant protein-based vaccine with potential approval in H1 2021Virtual R&D Day investor event today from 3:00-5:30 pm CET / 9:00-11:30 am ET PARIS - June 23, 2020 - Sanofi Chief Executive Officer Paul Hudson, Global Head of R&D John Reed, M.D., Ph.D., and members of the R&D and commercial leadership teams will provide an update on Sanofi's approach to deliver potentially transformative medicines to patients.

This event is the fourth of a five-part series highlighting how Sanofi is leading with innovation. The previous three events focused on the Phase 2 results of Sanofi's brain penetrant BTK inhibitor ('168), Sanofi's oncology pipeline progress, and future growth opportunities for Dupixent (dupilumab)1.

"Since last December, we have been making tremendous progress on our ability to grow a pipeline of potentially transformative treatments through a unique, adaptive strategy that best positions Sanofi to deliver on our goal of bringing practice-changing medicines and vaccines to patients," said Paul Hudson, Chief Executive Officer, Sanofi. "While we have greatly accelerated our efforts across six priority development programs, the momentum we are seeing can be found across our entire pipeline. This is largely driven by how we are leveraging our innovative technology platforms and the deep insights we have gained into patients' needs and disease pathways."

Source: West Corporation

Jun 19, 2020: Banco Santander Dupixent (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
Dupixent (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis

Dupixent included in China's list of overseas approved drugs that meet urgent clinical need Dupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammation PARIS and TARRYTOWN, NY - June 19, 2020 - The National Medical Products Administration (NMPA) in China has approved Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NMPA identified Dupixent as an overseas medicine considered urgently needed in clinical practice, leading to an expedited review and approval process.

"The limited treatment options in China for moderate-to-severe atopic dermatitis has left many patients and those who care for them coping with the physical and emotional burden of the disease," said Professor Zhang Jianzhong, chairman of the 13th session of the Dermatology and Venereology Branch of the Chinese Medical Association, and director of the Department of Dermatology, Peking University People's Hospital. "The availability of a targeted treatment like Dupixent provides hope to those seeking relief from the often-unbearable itch and other symptoms that can significantly impact the lives of adults living with this chronic disease."

Atopic dermatitis is a chronic inflammatory disease that often appears as a rash on the skin. Moderate-to-severe atopic dermatitis is characterized by rashes that can potentially cover much of the body, and can include intense, persistent itching, skin dryness and skin lesions including cracking, redness or darkness, crusting and oozing. Itch is one of the most burdensome symptoms for patients and can be debilitating. Inadequately controlled atopic dermatitis can have a physical, emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression, and feelings of isolation.

Source: West Corporation

Jun 19, 2020: Banco Santander Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors
Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors

Fitusiran, a novel RNAi therapy in development, has the potential to transform the treatment of hemophilia with a monthly, subcutaneous treatment for people with hemophilia A and B, with or without inhibitors Long-term exploratory data show prophylactic treatment with fitusiran provides a sustained reduction in annual bleed rates in moderate to severe hemophilia A and B patients, with or without inhibitors. Paris - June 19, 2020 - New data exploring the efficacy and safety of fitusiran, an investigational once-monthly, subcutaneously administered RNA interference (RNAi) therapy for the treatment of hemophilia A and B, with or without inhibitors, were shared today in a late-breaking presentation at the World Federation of Hemophilia Virtual Summit.

Long-term interim results from the Phase 2 open-label extension (OLE) study reinforce fitusiran's potential to restore hemostatic balance and to lower annualized bleed rates (ABRs) over a period up to 57 months.

"These new interim data support the potential of fitusiran to have a transformative impact on hemophilia management with the aim to provide patients with consistent bleed protection and only once monthly subcutaneous dosing," said Dietmar Berger, Global Head of Development, Sanofi. "We are continuing to advance our portfolio of factor and non-factor therapies that could offer people with hemophilia a broad range of therapeutic options to fit their individual needs. We continue to investigate the clinical profile of fitusiran in our Phase 3 ATLAS program with results expected in the first half of 2021 and look forward to offering this novel therapy to patients globally."

Source: West Corporation

Jun 16, 2020: Banco Santander Sanofi invests to make France its world class center of excellence in vaccine research and production
Sanofi invests to make France its world class center of excellence in vaccine research and production

Sanofi will invest more than half a billion euros to create a state-of-the-art vaccine production site (Neuville sur Saone) and a new research center (Marcy-l'Etoile) dedicated to vaccinesThe investments will strengthen Sanofi's leadership and capacity to advance the research of new innovative vaccines and produce them on a massive scale, in line with the corporate strategyThe innovative technologies of these new facilities will also provide Sanofi with the flexibility and agility needed to quickly respond to future pandemic risks PARIS - June 16, 2020 - Sanofi today detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest EUR610 million to create a new production site and research center in France with both dedicated to vaccines.

"Sanofi's heart beats in France. We have a long history and exceptional teams working throughout the country, embodying our strong values. By investing in a new industrial site and a R&D center, Sanofi positions France at the core of its strategy, aiming to make France a world-class center of excellence in vaccine research and production," said Paul Hudson, Chief Executive Officer at Sanofi. "Sanofi is a major healthcare player in France, in Europe, and worldwide. It is our responsibility to focus our resources and expertise against the current pandemic, but also to invest in preparing for future ones. We welcome the ongoing collaboration and commitment of the French authorities who we have been working alongside with the last several months to achieve this."

Source: West Corporation

Jun 11, 2020: Banco Santander Sanofi to present growth opportunities and development strategy for Dupixent (dupilumab) in type 2 inflammatory diseases
Sanofi to present growth opportunities and development strategy for Dupixent (dupilumab) in type 2 inflammatory diseases

Additional data contribute to the growing body of evidence demonstrating Dupixent's best in class safety profile combined with strong efficacy benefit for atopic dermatitis and further validate it as a standard of care treatment for asthma Dupixent's unique mechanism of action simultaneously inhibits IL-4 and IL-13, which play a key role in type 2 inflammation in multiple diseases Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease PARIS - June 11, 2020 - Sanofi commercial and R&D executives will provide an overview of the growth and development strategy for Dupixent (dupilumab) in the third of its five-part series to highlight Sanofi's progress in R&D. As announced in December 2019, Sanofi expects to deliver strong growth for Dupixent with the ambition of achieving more than EUR10 billion in peak sales driven by its selective mechanism of action targeting the type 2 inflammation pathway. Sanofi co-develops and co-commercializes Dupixent with Regeneron.

"By specifically targeting IL-4 and IL-13, Dupixent's mechanism of action is uniquely suited to help address conditions driven by type 2 inflammation," said John Reed, M.D., Ph.D., Global Head of Research and Development, Sanofi. "While atopic dermatitis and asthma are the foundational diseases where Dupixent was first approved for use, great opportunity exists across multiple diseases where type 2 inflammation plays a role. We are therefore aggressively pursuing clinical evaluation of additional indications where patients are urgently awaiting solutions for their unmet medical needs."

Source: West Corporation

Jun 08, 2020: Banco Santander Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease
Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease

Virtual scientific session June 16, 2020, 8:00-9:00am ET/2:00-3:00pm CETAvalglucosidase alfa receives FDA Breakthrough Therapy designation PARIS - June 8, 2020 - Sanofi will host a virtual scientific session to present data from the Phase 3 COMET trial of investigational enzyme replacement therapy (ERT) avalglucosidase alfa in patients with late-onset Pompe disease (LOPD).

The session, open to healthcare professionals and members of the media, will include a data presentation by Jordi Diaz-Manera, M.D., Ph.D., Professor of Neuromuscular Disorders, Translational Medicine and Genetics at the John Walton Muscular Dystrophy Research Center, Newcastle University, UK, and Professor of Neuromuscular Diseases, Translational Medicine and Genetics in the Neuromuscular Diseases Unit, Neurology department of Hospital de la Santa Creu, Barcelona, Spain.

The presentation will be followed by a Q&A session moderated by Alaa Hamed, M.D., MPH, MBA, Global Head of Medical Affairs, Rare Diseases at Sanofi.

The scientific session, endorsed by the COMET trial author group, is being scheduled as a result of the postponement of the July 2020 International Congress on Neuromuscular Diseases (ICNMD) due to the COVID-19 pandemic. Data from the Phase 3 COMET trial would have been presented at the July 2020 ICNMD. Pre-registration is required for the June 16, 2020 scientific session. Please click here to register.

Source: West Corporation

Jun 02, 2020: Banco Santander European Commission approves Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma
European Commission approves Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma

EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex) Sarclisa in combination with pom-dex significantly reduced the risk of progression or death by 40% versus pom-dex alone Multiple myeloma is the second most common blood cancer, with approximately 40,000 new cases per year in Europe PARIS - June 2, 2020 - The European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

Sarclisa is a monoclonal antibody (mAb) that binds to a specific epitope on the CD38 receptor of MM cells. "The EC approval of Sarclisa represents an important additional therapeutic option and may set a new standard of care for myeloma patients in Europe who are in need of new effective treatments because their disease has returned or they have become refractory to their previous treatment," said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. "Sarclisa in combination with pom-dex demonstrated median progression-free survival of nearly one year, a five-month improvement over pom-dex alone, in patients who had already failed at least two prior therapies."

Source: West Corporation

Jun 02, 2020: Banco Santander Sarclisa (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
Sarclisa (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma

Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) aloneSarclisa combination therapy delivered considerable depth of response, with undetectable levels of multiple myeloma (MM) in nearly 30% of patients with relapsed MM (MRD-negative 10-5 sensitivity) Results from first planned interim analysis of the Phase 3 IKEMA trial selected as late-breaking presentation at EHA25 Virtual Congress PARIS - June 2, 2020 - Sarclisa (isatuximab) added to carfilzomib and dexamethasone (Sarclisa combination therapy) reduced the risk of disease progression or death by 47% (hazard ratio 0.531, 99% CI 0.318-0.889, p=0.0007, n=179) compared to standard of care carfilzomib and dexamethasone (Kd) in patients (n=123) with relapsed multiple myeloma (MM). Sarclisa combination therapy compared to Kd alone showed a treatment benefit consistent across multiple subgroups.

These results from the Phase 3 IKEMA trial follow the topline announcement on May 12, 2020 that Sarclisa combination therapy met the trial primary endpoint at the pre-planned interim analysis. Interim results will be presented during the late-breaking session of the European Hematology Association (EHA) Virtual Congress (EHA25) on June 14, 2020 and will form the basis for global regulatory submissions later this year.

Source: West Corporation

Jun 02, 2020: Banco Santander Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline
Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline

PARIS - April 2, 2020 - Sanofi Chief Executive Officer Paul Hudson along with R&D and commercial leaders will provide an overview of Sanofi's oncology strategy and progress update of its related key products and pipeline programs. Sanofi's oncology strategy is focused on four core therapeutic areas with four anchor treatments the company believes have the potential to transform patient care.

The four areas of strategic focus within oncology, including multiple myeloma, skin, lung, and breast cancers. Sanofi's four anchor oncology treatments include Sarclisa (isatuximab-irfc), an anti-CD38 monoclonal antibody and Libtayo (cemiplimab-nwlc), a PD-1 checkpoint inhibitor1 and the pipeline programs - an investigational anti-CEACAM 5 antibody drug conjugate and SERD ('859), an investigational oral selective estrogen receptor degrader.

"We are rapidly building momentum with the execution of our oncology strategy, with several developments on both our pipeline and marketed treatments. Additionally, we are assembling a world-class development and marketing team to support our growth in this core area," said Hudson. "We believe our efforts and treatments have the potential to make a significant difference in the lives of people living with cancer."

"We've developed a focused oncology strategy, and are making significant clinical progress to support our ambitions," said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. "With a deep toolbox of therapeutic platforms enabling us to discover highly differentiated molecules, Sanofi has a tremendous opportunity to continue our momentum and build a sustainable presence in oncology."

Source: West Corporation

May 29, 2020: Banco Santander Sanofi names new leaders to Executive Committee
Sanofi names new leaders to Executive Committee

Natalie Bickford appointed Chief People OfficerArnaud Robert appointed Chief Digital Officer Julie Van Ongevalle appointed Head of Consumer Healthcare Thomas Triomphe appointed Head of Sanofi Pasteur PARIS - May 29, 2020 - Sanofi has named four new leaders to its Executive Committee. These appointments now complete the announced changes in February to further simplify the Company's executive leadership team.

The complete Sanofi Executive Committee now includes the four heads of the Company's global business units (Sanofi Genzyme, Sanofi Pasteur, General Medicines, and Consumer Healthcare) as well as the global Heads of Research and Development, Industrial Affairs, Finance, Human Resources, Legal and Digital.

"My objective has been to find the right blend of talented people that can make the whole team stronger than its individual parts. Sanofi needs people who can bring us new insights from the outside of the industry as well as people with world-class pharma expertise. We need leaders who come to Sanofi with a fresh perspective as well as leaders who have grown up within the company," says Paul Hudson, Chief Executive Officer at Sanofi. "I am confident in this team's capacity to inspire our people, execute our strategy and change the practice of medicine for patients."

Natalie Bickford, Executive Vice President, Chief People Officer

Natalie Bickford starts on August 1, and joins Sanofi from Merlin Entertainments, the world's second largest location-based entertainment business (which includes Legoland Resorts, Madame Tussaud's, SEALIFE aquariums, among other brands). At Merlin, she was responsible for 30,000 employees across Europe, North America, and Asia Pacific. Ms. Bickford brings a wealth of consumer-facing experience. She held previous Human Resources leadership positions at Sodexo, AstraZeneca, and Kingfisher, has consistently demonstrated passion for engaging teams and driving change in behaviors and culture. She also has a solid track record of transforming organizations, with a strong focus on inclusion and diversity.

Source: West Corporation

May 29, 2020: Banco Santander Libtayo (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
Libtayo (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

*Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years

PARIS and TARRYTOWN, N.Y. - May 29, 2020 - New, longer-term data were shared today for PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase 2 trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer. These results demonstrate both longer durability and higher complete response (CR) rates than previously reported. Furthermore, the data make up part of the largest and most mature prospective clinical dataset in patients with metastatic CSCC (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation. The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

"The three-year follow-up data demonstrate significant long-term outcomes with Libtayo, which is now standard-of-care for patients with advanced CSCC in many countries," said Dr. Danny Rischin, Director, Department of Medical Oncology at Peter MacCallum Cancer Centre, Victoria, Australia. "The Libtayo data on duration of response and overall survival provide new insights into the longer-term treatment of advanced CSCC, with the median still not reached for either measure. Remarkably, it is exciting to see the number of complete responses increase with longer follow-up, which reinforces the potential ongoing benefit of Libtayo treatment in this aggressive skin cancer."

Source: West Corporation

May 29, 2020: Banco Santander Sanofi announces closing of Regeneron stock sale
Sanofi announces closing of Regeneron stock sale

PARIS - May 29, 2020 - Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. This includes the previously announced overallotment option that has been fully exercised by underwriters. In addition, Sanofi announced the completion of Regeneron's repurchase of 9.8 million shares or approximately $5 billion in common stock directly from Sanofi.

As a result of the offering, Sanofi has sold its entire equity investment in Regeneron, (excluding 400,000 Regeneron shares, which Sanofi is retaining) for total gross proceeds amounting to $11.7 billion.

The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron. The Companies have had a successful and long-standing clinical and commercial collaboration dating back to 2003 that has resulted in five approved treatments to date with additional candidates currently in clinical development.

The registered offering was executed simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs & Co. LLC, together with Barclays, BNP PARIBAS, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers.

The shares offered to the public are offered pursuant to an existing effective shelf registration statement (including a base prospectus) that has been filed by Regeneron with the U.S. Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to and describing the terms of the offering has been filed by Regeneron with the SEC and is available on the SEC website at www.sec.gov. Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement if you request them by contacting: (1) BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com, or (2) Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com.

Source: West Corporation

May 26, 2020: Banco Santander Sanofi: FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS aloneThree-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%Safety consistent with the established safety profile of Dupixent across adult and adolescent atopic dermatitis patients PARIS and TARRYTOWN, N.Y. - May 26, 2020 - The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is the only biologic medicine approved for this patient population.

"This FDA approval is another milestone in the journey for Dupixent as an innovative biologic treatment for atopic dermatitis and other conditions driven in part by type 2 inflammation," said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. "Caregivers of children with moderate-to-severe atopic dermatitis and their physicians now have access to a first-in-class biologic with a proven safety profile, a factor that often plays a critical role in treatment decisions for younger patients. Additionally, improvements in itch and disease severity were observed as early as two weeks after the first dose and continued throughout active treatment, which is important for these children and their families."

Source: West Corporation

May 26, 2020: Banco Santander Sanofi announces pricing of Regeneron stock offering
Sanofi announces pricing of Regeneron stock offering

Sanofi announces sale of 21.6 million shares held in RegeneronGross proceeds of $11.1 billion to Sanofi to further Company's ability to execute innovation and growth strategy PARIS - May 26, 2020 - Sanofi today announced that it has agreed to sell 11.8 million shares of Regeneron, Inc. (NASDAQ: REGN) common stock through a registered offering at a price of $515.00 per share. As previously announced, Regeneron will repurchase 9.8 million shares or $5 billion in common stock from Sanofi at the offering price less the underwriting discount. Sanofi expects to use the net proceeds of the offering and the repurchase to further execute on its strategy to drive innovation and growth.

In connection with the offering, the underwriters have been granted an option to purchase up to 1.2 million additional Regeneron shares at the price payable by the underwriters in the offering, exercisable within the next 30 days. If the option is fully exercised, the offering and repurchase will together result in gross proceeds to Sanofi of $11.7 billion and the sale of Sanofi's entire holding in Regeneron, excluding 400,000 Regeneron shares that Sanofi is retaining.

The public offering is occurring simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs, together with Barclays, BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers.

The shares offered to the public are being offered pursuant to an existing effective shelf registration statement (including a base prospectus) that has been filed by Regeneron with the U.S. Securities and Exchange Commission (the "SEC"). Before you invest, you should read the prospectus in that registration statement and other documents Regeneron has filed with the SEC, including the preliminary prospectus supplement dated May 26, 2020, for more complete information about Regeneron and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement, when available, if you request them by contacting: (1) BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com, or (2) Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com.

Source: West Corporation

May 25, 2020: Banco Santander Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration

PARIS - May 25, 2020 - Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron.

A preliminary prospectus supplement relating to the offering of Regeneron's shares will be filed with the U.S. Securities and Exchange Commission. Sanofi currently holds approximately 23.2 million shares of Regeneron's common stock, representing approximately 20.6% ownership.

Regeneron has agreed to repurchase $5 billion of its stock from Sanofi conditional on completion of the proposed public offering. If the offering and repurchase are completed and the underwriters fully exercise their option to purchase additional shares1, Sanofi will continue to own approximately 400,000 shares of Regeneron's common stock, which Sanofi is retaining in support of the ongoing collaboration with Regeneron.

"Sanofi and Regeneron's collaboration has been one of the most productive in the industry, creating significant value for both companies but more importantly, resulting in five important medicines for patients. Sanofi remains committed to continuing our collaboration with Regeneron which remains an integral part of our overall strategy, and this decision was fully aligned with Regeneron, said Paul Hudson, Chief Executive Officer, Sanofi. "The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders. We believe the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth."

Source: West Corporation

May 22, 2020: Banco Santander Dupixent (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
Dupixent (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints

Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial69% reduction in disease symptoms with Dupixent, compared to 32% for placebo (p=0.0002)There are currently no FDA-approved treatments for eosinophilic esophagitis, a condition that impacts patients' ability to eat PARIS and TARRYTOWN, N.Y. - May 22, 2020 - Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints. Dupixent is the first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial. An ongoing Part B portion of the Phase 3 trial evaluates an additional Dupixent dosing regimen.

EoE is a chronic and progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing. If untreated, symptoms and inflammation can progress, causing functional damage and scarring of the esophagus. EoE can lead to esophageal food impaction, requiring immediate emergency room visits. Almost half of the patients in this trial had prior procedures such as dilation of their esophagus, and almost three-quarters had previously been treated with corticosteroids. In the U.S., there are approximately 160,000 patients with EoE who are currently treated, of which an estimated 50,000 have failed multiple treatments.There are currently no therapies approved by the U.S. Food and Drug Administration (FDA).

Source: West Corporation

May 18, 2020: Banco Santander Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event
Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event

Upcoming R&D sessions on oncology, Dupixent (dupilumab), and nirsevimabInitial session focused on brain-penetrant BTKi '168 Phase 2 dataVirtual R&D day event on June 23 to showcase Sanofi's industry leading platforms, unique capabilities, and innovative medicines to fuel future growth PARIS - May 18, 2020 - Sanofi announced today that it is hosting a series of interactive webcast events highlighting key priority pipeline programs that will conclude with the company's virtual R&D day event on Tuesday, June 23. The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofi's development strategy for its brain-penetrant BTKi'168 for multiple sclerosis in April. Upcoming sessions will discuss Sanofi's oncology strategy, line extension plans for Dupixent (dupilumab), and nirsevimab, the first time a monoclonal antibody potentially offers a population-based solution to prevent respiratory syncytial virus (RSV) for all infants.

"Over the coming weeks, we look forward to sharing the tremendous progress we've made in advancing our priority molecules and building a sustainable R&D engine," said John Reed, Global Head of Research and Development at Sanofi. "With a great team, deep therapeutic area expertise and an expanding toolbox of therapeutic platforms, Sanofi is poised to discover the next generation of life-changing medicines."

Source: West Corporation

May 14, 2020: Banco Santander FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease
FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease

*Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)

PARIS - May 14, 2020 - The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi's Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s.

If approved, sutimlimab would be the first and only approved treatment for these patients. The target action date for the FDA decision is November 13, 2020.

CAD is a chronic autoimmune hemolytic anemia that causes the body's immune system to mistakenly attack healthy red blood cells and cause their rupture (hemolysis). CAD patients may experience chronic anemia, profound fatigue, acute hemolytic crisis, and other potential complications, including an increased risk of thromboembolic events and early death.1,2,3 An estimated 5,000 people in the U.S. live with CAD.

"People living with cold agglutinin disease currently have no approved treatment option and experience chronic anemia and profound fatigue, which have a persistent and serious impact on their lives," said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. "Results from our 26-week pivotal Phase 3 study clearly demonstrated that sutimlimab had a clinically meaningful effect on complement-mediated hemolysis, which is the cause of anemia and fatigue. If approved, sutimlimab will be the first and only FDA-approved treatment to uniquely address C1-activated hemolysis and help alleviate the chronic disease burden for people with CAD."

Source: West Corporation

Share Capital

2021

Aug 25, 2021: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - July 2021
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,517,943,476 Registered office: 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395030844

Source: West Corporation

Jul 22, 2021: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - June 2021
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,517,943,476 Registered office: 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395030844

Source: West Corporation

Jun 30, 2021: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - May 2021
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,517,943,476 Registered office: 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395030844

Source: West Corporation

May 31, 2021: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - April 2021
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de lAutorite des Marches Financiers (Regulation of the French stock market authority)

Sanofi

a French societe anonyme with a registered share capital of 2,517,943,476

Registered office: 54, rue La Boetie - 75008 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395030844

* Pursuant to article 223-11 of the Reglement general de lAutorite des Marches Financiers.

This information is also available on the internet website of sanofi under Regulated Information in France:https://www.sanofi.com/en/investors/sanofi-share-and-adrs/share-overview/shares-and-voting-rights/

Attachment

EN_number_of_shares_and_voting_rights_April_2021

Source: West Corporation

2020

Dec 29, 2020: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - November 2020
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce

Source: West Corporation

Dec 10, 2020: Banco Santander announces Right Issue
Banco Santander has announced a 1 for 1 rights issue effective Friday, December 11. To subscribe to new shares the price has been fixed at 50.0c.

Nov 30, 2020: Banco Santander Sanofi: Disclosure of trading in own shares
Disclosure of trading in own shares from November 23, 2020 to November 27, 2020

Attachment

2020_11_27_Reporting_action_SANOFI_EN

Source: West Corporation

Nov 23, 2020: Banco Santander Sanofi: Disclosure of trading in own shares
Disclosure of trading in own shares from November 17, 2020 to November 20, 2020

Attachment

2020_11_20_Reporting_action_SANOFI_EN

Source: West Corporation

Sep 11, 2020: Banco Santander Sanofi : Information concerning the total number of voting rights and shares - July 2020
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de l'Autorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,517,873,886 EURRegistered office : 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844

Source: West Corporation

Jul 21, 2020: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - June 2020
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de l'Autorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,507,692,222 EURRegistered office : 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844

Source: West Corporation

Jun 19, 2020: Banco Santander Sanofi: Information concerning the total number of voting rights and shares - May 2020
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de l'Autorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,507,692,222 EURRegistered office : 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844

Source: West Corporation

Jun 03, 2020: Banco Santander Sanofi to launch "Action 2020", a worldwide employee stock purchase plan
Sanofi to launch "Action 2020", a worldwide employee stock purchase plan

A plan taking place in almost 75 countriesSubscription per five shares entitle the employee to one matching share1 PARIS - June 3, 2020 - Sanofi announces the launch of "Action 2020" on June 8, 2020, a worldwide stock purchase plan reserved for its employees, which should take place in almost 75 countries. Sanofi's strategy aims at providing long-term growth and value for its stakeholders while turning innovation into transformative medicines for patients. By doing such a capital increase, Sanofi intends to better associate its employees who are key contributors in this value creation, to the future development and results of the company.

On February 5, 2020 the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan. The subscription price is EUR70.67. It is equal to 80 % of the average of the opening price of the Sanofi share on Euronext Paris over the 20 stock exchange trading sessions preceding June 2, 2020. Any subscription per five shares as part of such issuance shall entitle the employee to one matching share. Subscriptions equal to or higher than 20 shares shall give right to 4 matching shares as an employer contribution. Employees may choose to subscribe a maximum of 1,500 shares within the limit of a maximum subscription amount which does not exceed 25% of their gross annual remuneration.

An eligibility condition of three months of seniority as at the closing date of the subscription period will be applied. The subscription period will run from June 8, 2020 (inclusive) until June 26, 2020 (inclusive).

Source: West Corporation

May 25, 2020: Banco Santander Sanofi: information concerning the total number of voting rights and shares, April 2020
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Reglement general de l'Autorite des Marches Financiers (Regulation of the French stock market authority)

Sanofia French societe anonyme with a registered share capital of 2,507,692,222 EURRegistered office : 54, rue La Boetie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844

Source: West Corporation

2018

Oct 17, 2018: Banco Santander announces Bonus issue
Banco Santander has announced a 123 for 1 bonus issue of shares, on Thursday, October 18.

Acquisitions

2021

Aug 03, 2021: Banco Santander Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areasFast tracks establishment of Sanofis recently announced mRNA Center of ExcellenceFull integration upgrades drug formulation capabilities and enhances US talent in a promising new technology PARIS and LEXINGTON, Mass August 3, 2021 As part of Sanofis endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.

Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics, said Paul Hudson, Sanofi Chief Executive Officer. A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space. We will also be able to accelerate our existing partnered programs already under development. Our goal is to unlock the potential of mRNA in other strategic areas such as immunology, oncology, and rare diseases in addition to vaccines.

Source: West Corporation

Jan 11, 2021: Banco Santander Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

Source: West Corporation

2020

Sep 28, 2020: Banco Santander Sanofi completes Principia Biopharma Inc. acquisition
The tender offer for all of the outstanding shares of Principia common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Friday, September 25, 2020. The minimum tender condition and all of the other conditions to the offer have been satisfied and on September 28, 2020, Sanofi and its wholly owned subsidiary Kortex Acquisition Corp. (aEURoePurchaseraEUR ), accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.

Source: West Corporation

Aug 28, 2020: Banco Santander Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.
Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.

Paris, August 28 2020 - Sanofi announced today that it intends to commence a tender offer (the "Offer") today to acquire all of the outstanding shares of common stock of Principia Biopharma Inc. ("Principia") for $100 per share in cash, without interest thereon and net of any applicable withholding taxes.

The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020 (as it may be amended from time to time, the "Merger Agreement"), by and among Principia, Sanofi and Kortex Acquisition Corp., a Delaware corporation and an indirect, wholly-owned subsidiary of Sanofi ("Purchaser").

The Offer is scheduled to expire one minute past 11:59 p.m., Eastern Time, on Friday, September 25, 2020, unless the Offer is extended in accordance with the Merger Agreement and the applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC").

The consummation of the Offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Principia common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions. Following the successful completion of the Offer, Purchaser will merge with and into Principia pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Principia continuing as the surviving corporation and becoming an indirect, wholly-owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger, the outstanding shares of common stock of Principia not tendered in the Offer will be converted into the right to receive the same $100 per share in cash that they would have received had they tendered their shares in the Offer.

Source: West Corporation

Aug 17, 2020: Banco Santander Sanofi to acquire Principia Biopharma
Sanofi to acquire Principia Biopharma

Further strengthens core R&D areas of autoimmune and allergic diseasesProvides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty paymentsAllows expansion of SAR442168 development program into other central nervous system diseases and therapeutic areasAdds clinically advanced oral BTK inhibitor rilzabrutinib with potential across a range of immunology and inflammation indications, complementing Sanofi's existing R&D pipeline PARIS and SOUTH SAN FRANCISCO, Calif. - August 17, 2020 - Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis). The Sanofi and Principia Boards of Directors unanimously approved the transaction.

"This acquisition advances our ongoing R&D transformation to accelerate development of the most promising medicines that will address significant patient needs," said Paul Hudson, Sanofi Chief Executive Officer. "The addition of multiple BTK inhibitors to our pipeline demonstrates our commitment to strategic product acquisitions in our priority therapeutic areas. Full ownership of our brain-penetrant BTK inhibitor '168 removes complexities for this priority development program and simplifies future commercialization."

Source: West Corporation

Litigation

2021

Jun 11, 2021: Banco Santander New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia

Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningfulFindings provide further evidence that sutimlimab results in rapid inhibition of C1-activated hemolysis within one week of treatment and had a sustained treatment effect throughout the study PARIS June 11, 2021 Results from Part A of CADENZA, a pivotal Phase 3 double-blind, placebo-controlled study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) without a recent history of blood transfusion (within the prior six months), will be presented in an oral session at the European Hematology Association 2021 Congress. The data demonstrated treatment with sutimlimab resulted in rapid and sustained inhibition of C1-activated hemolysis in people with CAD, noted within one week of treatment, and clinically significant improvements in hemoglobin and fatigue when compared to placebo during the course of the study.

Cold agglutinin disease causes the bodys immune system to mistakenly destroy its healthy red blood cells. People living with cold agglutinin disease experience the crippling impact of chronic hemolysis that can cause severe anemia, profound fatigue and can have acute hemolytic crisis, said principal investigator and presenting author Professor Alexander Roth, M.D., Department of Hematology and Stem Cell Transplantation, University Hospital, University of Duisburg-Essen, Germany. The positive evidence from the CADENZA trial demonstrate significant improvements in hemolysis and meaningful impact on key measures of anemia and fatigue.

Source: West Corporation

2020

Nov 19, 2020: Banco Santander FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
PARIS - November 14, 2020 - The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sutimlimab, an investigational monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease.

Source: West Corporation

Jun 16, 2020: Banco Santander Sanofi's investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease
Sanofi's investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease

Avalglucosidase alfa showed a 2.4-point improvement in percent-predicted forced vital capacity, an important measure of respiratory function in Pompe disease, compared to alglucosidase alfa (standard of care) Patients treated with avalglucosidase alfa walked 30 meters farther than those treated with standard of care, as measured by the 6-minute walk testGlobal regulatory submissions anticipated in the second half of 2020 PARIS - June 16, 2020 - Sanofi's investigational enzyme replacement therapy (ERT), avalglucosidase alfa, showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD) according to results from the Phase 3 trial presented today at a Sanofi-hosted scientific session. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD. These data will form the basis for global regulatory submissions anticipated in the second half of this year. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designations to avalglucosidase alfa for the treatment of patients with Pompe disease.

The trial primary endpoint evaluated the change in respiratory muscle function using percent-predicted forced vital capacity (FVC) in the upright position. Patients treated with avalglucosidase alfa had a 2.4-point greater improvement in percent-predicted FVC compared to patients treated with standard of care (95% CI, -0.13 / 4.99), a numerical improvement in respiratory function that surpassed the study-designed measure of non-inferiority (p=0.0074).

Source: West Corporation

Meetings

2021

May 19, 2021: Banco Santander Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancerData that reinforce Libtayo (cemiplimab-rwlc) as a standard of care in advanced non-melanoma skin cancer and advanced non-small cell lung cancer, including new data in historically underrepresented patients with brain metastasesLonger term data and new analyses for Sarclisa (isatuximab-irfc) further strengthen efficacy profile, including for elderly patients and patients with high-risk cytogenetic abnormalities PARIS May 19, 2021 New research being presented at the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8 highlights Sanofis transformative science and commitment to patient care across difficult-to-treat cancers, including multiple myeloma, skin, lung and breast cancers.Our pipeline of innovative investigational medicines continues to expand, supporting our goal to address critical gaps in treatment options for patients with cancers of high unmet need, says Peter C. Adamson, Global Development Head, Oncology at Sanofi. We look forward to presenting the latest data across our oncology portfolio and pipeline in four key areas multiple myeloma, skin cancers, lung cancers and breast cancer, including data supporting the potential for amcenestrant to become a best-in-class oral endocrine backbone therapy.

Early clinical data for amcenestrant, our investigational oral selective estrogen receptor degrader (SERD), show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer*

Source: West Corporation

May 03, 2021: Banco Santander Annual General Meeting of April 30, 2021
Board composition: renewals, ratification of a co-opting Director and appointment of one new Director

Source: West Corporation

Dividends

2019

Oct 12, 2019: Banco Santander announces dividend
Banco Santander today announced an interim dividend of 10.0c per share. The ex dividend date is Wednesday, October 30, 2019 and it is payable on Friday, November 01.

Apr 17, 2019: Banco Santander announces dividend
Banco Santander today announced a final dividend of 6.50c per share. The ex dividend date is Monday, April 29, 2019 and it is payable on Thursday, May 02.

Jan 10, 2019: Banco Santander announces dividend
Banco Santander today announced an interim dividend of 6.50c per share. The ex dividend date is Wednesday, January 30, 2019 and it is payable on Friday, February 01.

2018

Oct 16, 2018: Banco Santander announces dividend
Banco Santander today announced an interim dividend of 2.84c per share. The ex dividend date is Thursday, October 18, 2018 and the record date is Friday, October 19, 2018 and it is payable on Monday, November 05.

Jul 30, 2018: Banco Santander announces dividend
Banco Santander today announced an interim dividend of 6.50c per share. The ex dividend date is Monday, July 30, 2018 and it is payable on Wednesday, August 01.

Apr 27, 2018: Banco Santander announces dividend
Banco Santander today announced a final dividend of 6.0c per share. The ex dividend date is Friday, April 27, 2018 and it is payable on Wednesday, May 02.

Jan 16, 2018: Banco Santander announces dividend
Banco Santander today announced an interim dividend of 6.0c per share. The ex dividend date is Tuesday, January 30, 2018 and it is payable on Thursday, February 01.

2017

Oct 18, 2017: Banco Santander announces dividend
Banco Santander today announced an interim dividend of 4.0c per share. The ex dividend date is Wednesday, October 18, 2017 and it is payable on Friday, November 03.

People In Business


PIB_P_Snippet_WEEK

2021

Apr 27, 2021: Jose Antonio Alvarez CEO of Banco Santander in top 8% of price performers of Spanish stocks in past week
Jose Antonio Alvarez's performance as Chief Executive Officer of Banco Santander (MA:SAN) is ranked in the top 8% of BuySellSignals performers for the past week; a percentile ranking of 92.4 out of 182 companies listed in Spain.

PIB_P_Scorecard_year_top_H

2017

Oct 27, 2017: Homaira Akbari of Banco Santander in top quartile of Large MCap Director Scorecard for past year
Homaira Akbari's performance as Director of Banco Santander is ranked in the top quartile of BSS News Bites' Large MCap performers for the past year. The shares were up 33.4% in EUR terms for the year ended October 27, 2017. In USD terms the price rise was 49.5%. The present value of EUR1,000 (PV1000) invested on the appointment date of September 27, 2016 at close price of EUR3.55 is EUR1,684, for a capital gain of EUR604 and dividend reinvested of EUR80.

PIB_P_Scorecard_year_second_H
Nov 17, 2017: Ana Patricia Botin of Banco Santander in second quartile of Large MCap Director Scorecard for past year
Ana Patricia Botin's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past year. The shares were up 34% in EUR terms for the year ended November 17, 2017. In USD terms the price rise was 47.4%.

2018

Feb 13, 2018: Homaira Akbari of Banco Santander in second quartile of Large MCap Director Scorecard for past year
Homaira Akbari's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past year. The shares were up 13.3% in EUR terms for the year ended February 13, 2018. In USD terms the price rise was 35.8%. The present value of EUR1,000 (PV1000) invested on the appointment date of September 27, 2016 at close price of EUR3.52 is EUR1,652, for a capital gain of EUR557 and dividend reinvested of EUR94.

PIB_P_Snippet_TRS_5YR

2021

Jun 09, 2021: Jose Antonio Alvarez, Banco Santander Chief Executive Officer in top 15% of Spanish annual return
Jose Antonio Alvarez's performance as Chief Executive Officer of Banco Santander (MA:SAN) is ranked in the top 15% of BuySellSignals performers by 5-years average annual return of 19.4%. This corresponds to a percentile ranking of 85.6 out of 118 companies listed in Spain. A two-bagger, the present value of US$1,000 (PV1000) invested 5 years ago is now worth $2,424; a capital gain of $795 and dividend reinvested of $629. Banco Santander (MA:SAN) has soared EUR1.50 (or 79.5%) in the past five years to close at EUR3.38 today.Prices are adjusted for a bonus share. On November 16, 2020 shareholders received 1 additional share for every 23 shares held prior to that date.Compared with the IBEX 35 Index which has risen 3.7% over the same period, this is a relative price increase of 75.8%.In the past five years market cap has declined by EUR3,130,265,186 to EUR56.2 billion ($67.8 billion).

PIB_P_Scorecard_quarter_top_H
Jan 22, 2021: Jose Antonio Alvarez of Banco Santander in top 1% of Large MCap CEO Scorecard for past quarter
Jose Antonio Alvarez's performance as CEO of Banco Santander is ranked in the top 1% of BuySellSignals Large MCap performers for the past quarter; a percentile ranking of 99. The shares were up 168% in EUR terms for the quarter ended January 22, 2021. In USD terms the price rise was 185.3%.

PIB_P_TRS_1

2017

Sep 27, 2017: Homaira Akbari starts second year as Banco Santander Independent Director
27 September 2017
Homaira Akbari was appointed Independent Director of Banco Santander (MA:SAN) one year ago on September 27, 2016. The shares were up from EUR3.6 to EUR5.8 and the total annualized return to shareholders (TRS) since appointment is 68.4%. The present value of EUR1,000 (PV1000) invested on the appointment date is now worth EUR1,684, a gain of EUR615 and dividend reinvested of EUR70.

2019

Sep 27, 2019: Homaira Akbari starts fourth year as Banco Santander Independent Director
Friday September 27, 2019
Homaira Akbari was appointed Independent Director of Banco Santander (MA:SAN) three years ago on September 27, 2016. The shares were up from EUR3.3 to EUR3.7 and the total annualized return to shareholders (TRS) since appointment is 8.6%. The present value of EUR1,000 (PV1000) invested on the appointment date is now worth EUR1,280, a gain of EUR128 and dividend reinvested of EUR152.

PIB_P_Snippet_TRS_3YR

2021

Jul 08, 2021: Jose Antonio Alvarez, Banco Santander Chief Executive Officer in top 19% of Spanish annual return
Jose Antonio Alvarez's performance as Chief Executive Officer of Banco Santander (MA:SAN) is ranked in the top 19% of BuySellSignals performers by 3-years average annual return of 12.4%. This corresponds to a percentile ranking of 81.2 out of 117 companies listed in Spain. The present value of US$1,000 (PV1000) invested 3 years ago is now worth $1,427; a capital gain of $238 and dividend reinvested of $188. Banco Santander (MA:SAN) has jumped 58.91 EURcents (or 23.8%) in the past three years to close at EUR3.06 today.Prices are adjusted for a bonus share. On November 16, 2020 shareholders received 1 additional share for every 23 shares held prior to that date.Compared with the IBEX 35 Index which has fallen 12.7% over the same period, this is a relative price increase of 36.5%.In the past three years market cap has declined by EUR25,908,252,678 to EUR50.9 billion ($60 billion).

Aug 06, 2021: Jose Antonio Alvarez, Banco Santander Chief Executive Officer in top 20% of Spanish annual return
Jose Antonio Alvarez's performance as Chief Executive Officer of Banco Santander (MA:SAN) is ranked in the top 20% of BuySellSignals performers by 3-years average annual return of 13.6%. This corresponds to a percentile ranking of 80.7 out of 109 companies listed in Spain. The present value of US$1,000 (PV1000) invested 3 years ago is now worth $1,470; a capital gain of $308 and dividend reinvested of $162. Banco Santander (MA:SAN) has jumped 76.04 EURcents (or 30.8%) in the past three years to close at EUR3.23 today.Prices are adjusted for a bonus share. On November 16, 2020 shareholders received 1 additional share for every 23 shares held prior to that date.Compared with the IBEX 35 Index which has fallen 8.8% over the same period, this is a relative price increase of 39.6%.In the past three years market cap has declined by EUR22,010,118,887 to EUR53.7 billion ($63.5 billion).

PIB_P_Scorecard_quarter_second_H

2018

Jan 26, 2018: Juan Rodriguez Inciarte of Banco Santander in second quartile of Large MCap Director Scorecard for past quarter
Juan Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were up 4.2% in EUR terms for the quarter ended January 26, 2018. In USD terms the price rise was 13.8%.

Mar 28, 2018: Ana Patricia Botin of Banco Santander in second quartile of Large MCap Director Scorecard for past quarter
Ana Patricia Botin's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were down 3.9% in EUR terms for the quarter ended March 28, 2018. In USD terms the price rise was 0.4%.

Apr 30, 2018: Juan Rodriguez Inciarte of Banco Santander in second quartile of Large MCap Director Scorecard for past quarter
Juan Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were down 9.2% in EUR terms for the quarter ended April 30, 2018. In USD terms the price rise was 0.6%.

May 16, 2018: Ana Patricia Botin-Sanz de Sautuola y O'Shea of Banco Santander in second quartile of Large MCap Director Scorecard for past quarter
Ana Patricia Botin-Sanz de Sautuola y O'Shea's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were down 4% in EUR terms for the quarter ended May 16, 2018. In USD terms the price rise was 0.6%.

Jun 01, 2018: Homaira Akbari of Banco Santander in second quartile of Large MCap Director Scorecard for past quarter
Homaira Akbari's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were down 14.3% in EUR terms for the quarter ended June 01, 2018. In USD terms the price rise was 0.6%. The present value of EUR1,000 (PV1000) invested on the appointment date of September 27, 2016 at close price of EUR3.48 is EUR1,467, for a capital gain of EUR367 and dividend reinvested of EUR100.

2019

Jan 29, 2019: Juan Rodriguez Inciarte of Banco Santander in second quartile of Large MCap Director Scorecard for past quarter
Juan Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the second quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were up 5.3% in EUR terms for the quarter ended January 29, 2019. In USD terms the price rise was 5.7%.

PIB_P_Scorecard_quarter_third_H

2018

Sep 27, 2018: Ana Patricia Botin of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Ana Patricia Botin's performance as Director of Banco Santander is ranked in the third quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were down 0.9% in EUR terms for the quarter ended September 27, 2018. In USD terms the price rise was 0%.

2019

Feb 21, 2019: Matias Rodriguez Inciarte of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Matias Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the third quartile of BSS News Bites' Large MCap performers for the past quarter. The shares were up 1.4% in EUR terms for the quarter ended February 21, 2019. In USD terms the price rise was 2.2%.

Mar 27, 2019: Homaira Akbari of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Homaira Akbari's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 25.3. The shares were up 6.8% in EUR terms for the quarter ended March 27, 2019. In USD terms the price rise was 5.7%. The present value of EUR1,000 (PV1000) invested on the appointment date of September 27, 2016 at close price of EUR3.33 is EUR1,388, for a capital gain of EUR247 and dividend reinvested of EUR141.

Apr 30, 2019: Juan Rodriguez Inciarte of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Juan Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 32.2. The shares were up 8% in EUR terms for the quarter ended April 30, 2019. In USD terms the price rise was 3.1%.

Jun 27, 2019: Matias Rodriguez Inciarte of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Matias Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 42.9. The shares were down 0.9% in EUR terms for the quarter ended June 27, 2019. In USD terms the price rise was 0.9%.

Nov 25, 2019: Juan Rodriguez Inciarte of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Juan Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 37.8. The shares were up 7.6% in EUR terms for the quarter ended November 25, 2019. In USD terms the price rise was 1.9%.

Dec 18, 2019: Matias Rodriguez Inciarte of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Matias Rodriguez Inciarte's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 45.3. The shares were up 6.8% in EUR terms for the quarter ended December 18, 2019. In USD terms the price rise was 3.2%.

2020

Jan 02, 2020: Ana Patricia Botin-Sanz de Sautuola y O'Shea of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Ana Patricia Botin-Sanz de Sautuola y O'Shea's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 35.2. The shares were up 7.3% in EUR terms for the quarter ended January 02, 2020. In USD terms the price rise was 2.4%.

Feb 13, 2020: Ana Patricia Botin of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Ana Patricia Botin's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals News Bites' Large MCap performers for the past quarter; a percentile ranking of 46.8. The shares were up 9% in EUR terms for the quarter ended February 13, 2020. In USD terms the price rise was 2.3%.

Jun 17, 2020: Homaira Akbari of Banco Santander in third quartile of Large MCap Director Scorecard for past quarter
Homaira Akbari's performance as Director of Banco Santander is ranked in the third quartile of BuySellSignals Large MCap performers for the past quarter; a percentile ranking of 27.2. The shares were up 10.9% in EUR terms for the quarter ended June 17, 2020. In USD terms the price rise was 10.7%.

PIB_P_Snippet_MONTH_TR

2021

May 25, 2021: Jose Antonio Alvarez CEO of Banco Santander in top 6% of price performers of Spanish stocks in past month
Jose Antonio Alvarez's performance as Chief Executive Officer of Banco Santander (MA:SAN) is ranked in the top 6% of BuySellSignals performers for the past month; a percentile ranking of 94.1 out of 182 companies listed in Spain.